Companies / Israel
Struggle For Finance Leads BioLineRX To Consider Dual Listing
October 2007 | Company Finance AlertIsrael's BioLineRX is investigating the possibility of a listing on the US NASDAQ as the clinical research firm considers how to raise capital for its R&D activities. BioLineRX focuses on running clinical trials for promising compounds developed by universities and biotech firms, a strategy that requires significant capital and investors that are willing to risk a loss should the drug
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
